Convergent Therapeutics

Convergent Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, developing next-generation targeted radiotherapies for cancer. Founded in 2020 by Philip Kantoff, the company builds alpha radioantibodies that pair a humanized monoclonal antibody against prostate-specific membrane antigen (PSMA) with the alpha emitter actinium-225, delivering short-range, high-energy alpha radiation to tumor cells. Its lead candidate, CONV01-alpha (rosopatamab tetraxetan), is in the Phase 2 CONVERGE-01 trial in metastatic castration-resistant prostate cancer, including patients previously treated with Lu-177 PSMA radioligand therapy, with a pivotal Phase 3 planned. Convergent announced a $90 million Series A financing in 2023. The company publishes a corporate website covering its pipeline, technology, scientific publications and press, but operates no public developer program, API, SDK, or machine-readable API contract.

Convergent Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Radiopharmaceuticals.

Convergent Therapeutics’ developer surface includes product news, engineering blog, and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsOncologyRadiopharmaceuticalsClinical TrialsLife SciencesHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 8.9/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/convergent-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

PressReleases

PressReleases

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

About

News

Blog

BlogFeeds

LinkedIn

Other 4

Properties that don't map to a standard resource type

Team

Products

Research

Marketplace

Source (apis.yml)

aid: convergent-therapeutics
name: Convergent Therapeutics
description: Convergent Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, developing
  next-generation targeted radiotherapies for cancer. Founded in 2020 by Philip Kantoff, the company builds alpha radioantibodies
  that pair a humanized monoclonal antibody against prostate-specific membrane antigen (PSMA) with the alpha emitter actinium-225,
  delivering short-range, high-energy alpha radiation to tumor cells. Its lead candidate, CONV01-alpha (rosopatamab tetraxetan),
  is in the Phase 2 CONVERGE-01 trial in metastatic castration-resistant prostate cancer, including patients previously treated
  with Lu-177 PSMA radioligand therapy, with a pivotal Phase 3 planned. Convergent announced a $90 million Series A financing
  in 2023. The company publishes a corporate website covering its pipeline, technology, scientific publications and press,
  but operates no public developer program, API, SDK, or machine-readable API contract.
image: https://convergentrx.com/wp-content/uploads/2024/10/Convergent-Therapeutics-logo.svg
url: https://raw.githubusercontent.com/api-evangelist/convergent-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: enriched-no-api-surface
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Radiopharmaceuticals
- Clinical Trials
- Life Sciences
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/convergent-therapeutics-domain-security.yml
- type: Website
  url: https://convergentrx.com/
- type: About
  url: https://convergentrx.com/team/
- type: Team
  url: https://convergentrx.com/team/
- type: Products
  url: https://convergentrx.com/pipeline/
- type: Solutions
  url: https://convergentrx.com/technology/
- type: Research
  url: https://convergentrx.com/publications/
- type: News
  url: https://convergentrx.com/press/
- type: PressReleases
  url: https://convergentrx.com/press/
- type: Blog
  url: https://convergentrx.com/press/
- type: BlogFeeds
  url: https://convergentrx.com/feed/
- type: PrivacyPolicy
  url: https://convergentrx.com/privacy-policy/
- type: Contact
  url: mailto:info@convergentrx.com
- type: LinkedIn
  url: https://www.linkedin.com/company/convergent-therapeutics
- type: Marketplace
  url: https://forgeglobal.com/convergent-therapeutics_stock/
- type: LLMsTxt
  url: llms/convergent-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 3
  pass: local-v1